Skip to search formSkip to main contentSkip to account menu

BCX1777

Known as: BCX-1777 
National Institutes of Health

Related topics

Related topics

2 relations
forodesine hydrochloride

Broader (1)

immucillin H

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been… 
2009
2009
Mechanism of thiol-supported arsenate reduction mediated by phosphorolytic-arsenolytic enzymes: II. Enzymatic formation of arsenylated products susceptible for reduction to arsenite by thiols.
Enzymes catalyzing the phosphorolytic cleavage of their substrates can reduce arsenate (AsV) to the more toxic arsenite (AsIII… 
Review
2008
Review
2008
Novel purine nucleoside analogues for hematological malignancies.
Recently, the search for more effective and safer antineoplastic agents has led to synthesis and introduction into preclinical… 
2006
2006
Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).
Background: Forodesine, a potent, rationally designed purine nucleoside phosphorylase inhibitor, has shown clinical activity in T… 
2006
2006
Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.
Abstract Background: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally… 
Highly Cited
2005
Highly Cited
2005
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme… 
2004
2004
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.
The profound suppression of T-cell immunity seen in patients with an inherited PNP deficiency supports the potential application… 
Review
2004
Review
2004
Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Purine nucleoside phosphorylase (PNP)-deficient children exhibit profound impairment in the T-cell component of their immune… 
2003
2003
Arsenate reduction in human erythrocytes and rats--testing the role of purine nucleoside phosphorylase.
Reduction of the pentavalent arsenate (AsV) to the thiol-reactive arsenite (AsIII) toxifies this environmentally prevalent form… 
2002
2002
Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)